Roberto Contieri

❓️Can we avoid ReTURBT in selected patients with T1 NMIBC? ✅️ According to our study YES! 👥️A response-based approach can spare up to 71% of ReTURBT reducing overtreatment Full paper➡️euoncology.europeanurology.com/article/S2588-… @EurUrolOncol @urotoday @Uroweb @oncodaily @IBCG_BladderCA

Synergy 2026: A Global Exchange on Prostate, Kidney, and Bladder Cancer - Roberto Contieri (@RobertoContieri) oncodaily.com/voices/roberto… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX

SYNERGY 2026 🗓️ 28-29 May 2026 📍 Naples, Italy Preliminary Program: bit.ly/4w05Zbf ✉️ Information & participation: marketing@congredi.it - pandolfosavio@gmail.com

To escalate or de-escalate treatment in BCG-naive HR NMIBC? Our thoughts on the recent JCOG1019 trial by Kitamura et al @EUplatinum Free access to full text 👇🏽 sciencedirect.com/science/articl… @RobertoContieri @LAUrology_NL @UroDocAsh

A multi-center study examines maintenance schedules for intermediate-risk #NMIBC. @RobertoContieri @IstTumori joins @UroDocAsh @UTMDAnderson to discuss the results which include two-year recurrence-free survival of 55% with no maintenance versus 78% with any maintenance. Classification and regression tree analysis identified optimal cutoff at more than six monthly instillations. #WatchNow on UroToday > bit.ly/3OEHP5m

Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial by Roberto Contieri et al Read the full article: buff.ly/AcADjoA We thank the authors for trusting EUO to publish your work @robertocontieri @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @UroDocAsh @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

The International Bladder Cancer Group Travel Award to support outstanding fellows and early-career academic faculty committed to advancing the field of bladder cancer is now offered annually to provide emerging leaders the opportunity to participate in the IBCG Annual Retreat. Details at link: ibcg.info/ibcg-2025-trav… #BladderCancer #IBCG26

Pleased to share that the 2026 @NCCN Bladder Cancer Guidelines now incorporate the @IBCG_BladderCa risk stratification framework for intermediate-risk NMIBC. A milestone reflecting more than a decade of collaborative work by colleagues worldwide einpresswire.com/article/901009… @UrogerliMD @drtanws @shilpaonc @pjhensley11 @mouwlab @AndreaNecchi @LAUrology_NL @AmirHorowitz @karima_oualla @PGrivasMDPhD @paolo_gontero @pcvblack @MaxKates @SpiessPhilippe @RobertoContieri @KKBree @LauraBukavinaMD @MRoupret @joanfundi @UroToday @BladderCancerUS @WorldBladderCan

We validated BCG failure classifications ~5-year progression ≈30% in both BCG-exposed and BCG-unresponsive groups—but salvage RC is used more often in BCG-unresponsive pts doi.org/10.1111/bju.70… @Pietro9609 @UroMoschini @BenjaminPradere @RobertoContieri @SBoorjian @BJUIjournal

Roberto Contieri Shares Key Insights on Bladder Cancer Care at EAU 2026 @RobertoContieri oncodaily.com/voices/roberto… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

@tonivilaseca presenting promising early data for intravesical erdafitinib (Erda-iDRS) “TAR 210” in NMIBC presented at #EAU26 ➡️ 83% 12-mo RFS as adjuvant therapy in HR NMIBC (n=26) ➡️ 89% CR at 6 months in IR NMIBC ablative cohort Targeted #FGFR therapy moving earlier into NMIBC disease states. @JoshMeeks @DrFelixGuerrero @IBCG_BladderCA @BladderCancerUS

Which #NMIBC patients may safely receive de-intensified treatment? At #EAU26 @RobertoContieri (@istitutotumori) discusses risk stratification for de-escalation, findings from the ROBUUST database on histological subtypes, and optimizing mitomycin C maintenance in intermediate-risk Ta disease @Uroweb #GUsm #BladderCancer

State-of-the-art lecture treatment de-intensification in #NMIBC. Presentation by @RobertoContieri @IstTumori. #EAU26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/4sgk02k @Uroweb

#EAU26 @RobertoContieri “Less is more” in select NMIBC 🔹 Office-based fulguration 🔹 Active surveillance 🔹 Chemoablation 🎯 The key is patient selection. @uroweb @UroToday

Excellent case for de-escalating management of LGTa #bladdercancer by @RobertoContieri LG Ta has low progression risk & negligible CSM yet… We overtreat LGTa We oversurveil LGTa Active surveillance in well selected pts is safe, cost-effective & maintains excellent QoL #EAU26

Day 2 #EAU26 morning session jam packed with urothelial carcinoma updated and pro/con.. see everyone there ! @MRoupret Laura Mertens @tbivala1 @spsutkaMD @RobertoContieri @tompowles1

Standing room only … but there are some seats open in the front; come on in! ☄️ Rapid Fire Debates: common problems and controversies in #BladderCancer ; 9th Edition Orange Area eURO 2: #EAU26 @ParamMariappan @LAUrology_NL @achoud72 @MRoupret @jteoh_hk @paolo_gontero @BenjaminPradere @BogdanaSchmidt @MattGalsky @NehaVapiwala @tompowles1 #UroTwitter @MaartenAlbersen

Niyati and Nik – thank you for hosting such a wonderful dinner and for the warm hospitality. A truly perfect start to #EAU26. Grateful to everyone who came out to celebrate and spend time together @niyatilobo @nikhilvasdevuro @AlisonBirtle @ParamMariappan @RobertoContieri @drtanws @jteoh_hk

Initial case series and perioperative outcomes of single-port robotic radical prostatectomy: the Italian experience techscience.com/CJU/v33n1/6644… This study reports the first European case series of single-port robot-assisted radical prostatectomy (SP-RARP) using the Da Vinci SP system at the Istituto Nazionale Tumori di Napoli. Sixteen patients underwent extraperitoneal SP-RARP with no conversions or complications. Median console time was 110 minutes and median blood loss 175 cc, with discharge on postoperative day one. The findings demonstrate feasibility for experienced robotic surgeons, though larger studies are needed to assess long-term oncologic and functional outcomes. #ProstateCancer @PandolfoSD @robertocontieri

Looking forward to attending one of the most thought-provoking sessions of #EAU26. "Bladder Cancer rapide fire debate" is always a valuable opportunity for high-level discussion and fresh perspectives in our field.